Nasdaq-listed firm announces $50M Hyperliquid reserve — will HYPE rise further? 6 seconds ago

cryptonews
06-18

A Nasdaq-listed biotech company is betting big on crypto with a $50 million move into Hyperliquid’s HYPE token.

According to a June 17 press release from Eyenovia, Inc., a U.S.-based ophthalmic technology firm, the company has secured $50 million in private equity financing to accumulate over 1 million Hyperliquid (HYPE) tokens. With this move, Eyenovia becomes the first publicly traded U.S. company to hold HYPE in its treasury and operate as a Hyperliquid blockchain validator.

The funding deal includes convertible preferred shares and warrants, which could raise up to $150 million if fully exercised. Alongside the announcement, Eyenovia named Hyunsu Jung as chief investment officer and board member to oversee the new digital asset strategy.

“We’re pleased to join the growing number of companies adopting cryptocurrency treasury strategies,” said chief executive officer Michael Rowe. “We believe this move supports long-term capital appreciation and shareholder value.”

Jung called HYPE “the most robust digital asset,” citing Hyperliquid’s rapid growth and leading onchain revenue. HYPE ranks as the 12th-largest cryptocurrency by market cap, having surged 380% from its April low to an all-time high of $45.57 on June 16. At press time, HYPE is trading at $40.24, down 11% from its peak.

Hyperliquid, a high-speed Layer 1 blockchain optimized for perpetuals trading, has seen a wave of adoption. In the past 30 days, it has accounted for 60% of the total onchain perps volume, according to data from a Dune Analytics dashboard. Monthly perps volume has topped $250 billion, making it a strong competitor to centralized exchanges such as Binance.

Eyenovia plans to execute a staking strategy with its HYPE holdings and use Anchorage Digital to secure its assets. In addition, the company will rebrand to “Hyperion DeFi”  and change its ticker symbol to HYPD.

Eyenovia will keep working on its flagship Optejet eye treatment device, which is expected to receive FDA registration by September, while branching out into cryptocurrency. If other public companies follow Eyenovia’s lead, Hyperliquid could see a sharp increase in token demand and network effects, potentially positioning it as a top 10 blockchain by market capitalization.

Read more: No VC, $1B Trades, and a 300% Rally — what makes Hyperliquid crypto tick?

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10